Innovate UK, LifeArc, and Medicines Discovery Catapult (MDC) have joined forces to create PACE (Pathways to Antimicrobial Clinical Efficacy), a £30 million initiative supporting early-stage innovation against antimicrobial resistance (AMR) to save lives. PACE has today (19 October 2023) announced its first funding call with up to £10 million available to support innovators developing new antimicrobials.
The UK's largest public-private initiative targeting early-stage antimicrobial drug and diagnostic discovery has been introduced by Innovate UK, LifeArc and Medicines Discovery Catapult (MDC). Click to read more.
Today (16 March 2023), Cystic Fibrosis (CF) Syndicate in Antimicrobial Resistance (AMR) announces a £3 million Collaborative Discovery Programme for drug discovery innovators to accelerate the development of new treatments for people with CF.
CF AMR Syndicate Launches £3 million Collaborative Discovery Programme Funding New Antimicrobials to Treat Lung Infections in People with Cystic Fibrosis 16 March 2023 Today (16 March 2023), Cystic Fibrosis (CF) Syndicate in Antimicrobial Resistance (AMR) announces a £3 million Collabor.
"This funding call is part of LifeArc's £100m programme to accelerate scientific innovation for people living with CF and bronchiectasis. Click to read more.